한빛사논문
- 조회307
Chanhee Jeon 1, Hayoung Jun 1, Sooyeon Kim 1, Nanhee Song 1, Manseok Yang 1, Changjin Lim 2, Dongwon Lee 1,3
1Department of Bionanotechnology and Bioconvergence Engineering, Jeonbuk National University, Jeonju, Chonbuk 54896, Republic of Korea.
2Department of Pharmacy, Jeonbuk National University, Jeonju, Chonbuk 54896, Republic of Korea.
3Department of Polymer-Nano Science and Technology, Jeonbuk National University, Jeonju, Chonbuk 54896, Republic of Korea.
Corresponding Author : Dongwon Lee
Abstract
Liposomes have been extensively explored as drug carriers, but their clinical translation has been hampered by their low drug-loading content and premature leakage of drug payloads. It was reasoned that vesicle-forming prodrugs could be incorporated into the lipid bilayer at a high molar fraction and therefore serve as a therapeutic agent as well as a structural component in liposomal nanomedicine. Boronated retinoic acid (BORA) was developed as a prodrug, which can self-assemble with common lipids to form liposomes at a high molar fraction (40%) and release all-trans retinoic acid (atRA) and hydroxybenzyl alcohol (HBA) simultaneously, in response to hydrogen peroxide (H2O2). Here, we report fucoidan-coated BORA-incorporated liposomes (f-BORALP) as clot-targeted antithrombotic liposomal nanomedicine with H2O2-triggered multiple therapeutic actions. In the mouse model of carotid arterial thrombosis, f-BORALP preferentially accumulated in the injured blood vessel and significantly suppressed thrombus formation, demonstrating their potential as targeted antithrombotic nanomedicine. This study also provides valuable insight into the development of vesicle-forming and self-immolative prodrugs to exploit the benefits of liposomal drug delivery.
논문정보
- Research article
- 2023년 02월 (BRIC 등록일 2023-05-10)
- 국내 연구진
- 바이오·의료융합 > 바이오센싱 및 나노바이오물질
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
